Buyer	NHS England — not a council we hold
Supplier	Accord-UK Ltd
Supplier	AOP Orphan Ltd
Supplier	Arcadia Pharma Ltd T/A Arcadia Medical
Supplier	Ascend Laboratories UK Ltd
Supplier	Aspen Pharmacare UK Limited
Supplier	Baxter Healthcare Ltd
Supplier	Bayer plc
Supplier	Beaumont Pharma Ltd
Supplier	Bristol Laboratories Limited
Supplier	Brown & Burk UK Ltd
Supplier	Chiesi Limited
Supplier	Cipla
Supplier	Clydesdale Pharma ltd
Supplier	Correvio GmbH
Supplier	Crescent Pharma Ltd
Supplier	Derma UK
Supplier	Dr Falk Pharma UK Ltd
Supplier	Drugsrus Ltd
Supplier	Eramol (UK) Ltd
Supplier	Evolan Pharma
Supplier	Ferring Pharmaceuticals Ltd
Supplier	Focus Pharmaceuticals Ltd
Supplier	Galen Limited
Supplier	Galvany Pharma Ltd
Supplier	Genesis Pharmaceuticals Ltd
Supplier	JCSH Pharma Ltd
Supplier	Krka UK ltd
Supplier	Kyowa Kirin Ltd
Supplier	LogixX Pharma Ltd
Supplier	Lundbeck Limited
Supplier	Lupin Healthcare (UK) Limited
Supplier	Macure Pharma ApS
Supplier	Manx Healthcare Ltd
Supplier	Medley Pharma Ltd
Supplier	MSN Laboratories Europe Limited
Supplier	Necessity Supplies Limited
Supplier	Neon Healthcare Ltd
Supplier	Norgine Pharmaceuticals Limited
Supplier	Oralieve UK Ltd
Supplier	Orion Pharma (UK) Ltd
Supplier	Phoenix Lab
Supplier	P M Pharma
Supplier	Reckitt Benckiser
Supplier	Recordati Pharmaceuticals Ltd
Supplier	Reig Jofre UK limited
Supplier	Relonchem Ltd
Supplier	Rivopharm UK Ltd
Supplier	RPH Pharmaceuticals AB
Supplier	Scope Ophthalmics
Supplier	Stirling Anglian Pharmaceuticals Ltd
Supplier	Strandhaven Ltd t/a Somex Pharma
Supplier	Strides Pharma Uk LTD
Supplier	Synchrony
Supplier	Syri Limited (T/A Thame Laboratories)
Supplier	Takeda UK Ltd
Supplier	Tetris Pharma Lts
Supplier	Thea Pharmaceuticals Limited
Supplier	Tillomed Laboratories ltd
Supplier	Torrent Pharma UK Ltd
Supplier	Typharm Ltd
Supplier	Uni Health Distribution Ltd
Supplier	Vantage Pharmaceuticals Ltd
Supplier	Waymade PLC

Invitation to offer for NHS National Generic Pharmaceuticals - Wave 14c Offer reference number: CM/PHG/22/5672 Period of framework agreement: The total maximum duration of the framework agreement to be no more than 36 months with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 48 months. Potential periods of call-offs under the framework agreement: Orals (plus non-parenteral) Products: All Regions (CESW/LSNE/NWLN):01/06/2024 to 31/05/2027 (36 Months) Hospital Only Products: DLS & DNE: 01/06/2024 to 31/05/2026(24 months) Hospital Only Products(Housekeeping): DLN & DNW: 01/06/2024 to 31/01/2025(8 months) DCE & DSW: 01/06/2024 to 30/09/2025(16 months)

Runs	1 Jun 2024 to 31 May 2027
OCID	ocds-b5fd17-473f438e-1571-48a1-aa1d-5a4342588eda
Notice	Read it on Contracts Finder

Figures are as published An award value in OCDS may be a framework ceiling rather than a sum anyone expects to spend, so a large figure here is not evidence of a large purchase.